IGF1 and neoplasm: Several studies have shown that decreasing activity through the insulin/insulin-like growth factor 1 (IGF-1) signaling pathway (either genetically or due to tumor-based production of the insulin/IGF antagonist ImpL2) leads to muscle wasting and affects genes encoding metabolic enzymes as well as macromolecule stores [43–47].